A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery.
Jeroen H A CreemersWillem Joost LesterhuisNiven MehraWinald R GerritsenCarl G FigdorIngrid Jolanda M De VriesJohannes C TextorPublished in: Journal for immunotherapy of cancer (2022)
These findings have two important implications for clinical oncology. First, the apparent conundrum that ICI induces substantial benefits in some patients yet completely fails in others could be, to a large extent, explained by the presence of a tipping point. Second, predictive biomarkers for immunotherapy should ideally combine both immunological and tumor-related markers, as a patient's distance from the tipping point can typically not be reliably determined from solely one of these. The notion of a tipping point in cancer-immune dynamics helps to devise more accurate strategies to select appropriate treatments for patients with cancer.